The key COVID-19 findings in neurology, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
35cited sources
20available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY30%
Pooled brain fog prevalence was 30% in Long COVID
A systematic review estimated brain fog prevalence at 30% and cognitive impairment prevalence at 25% in Long COVID populations.
Both pooled prevalence estimates come from one systematic review of Long COVID populations. Definitions and contributing populations are not detailed in this summary.
See the evidence
Pooled prevalence of brain fog in long COVID populations
30% 95% CI: 28-32
Faseeh, Ahmar et al.. Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.. Medicine. 2026.
Pooled prevalence of cognitive impairment in long COVID populations
25% 95% CI: 23-27
Faseeh, Ahmar et al.. Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.. Medicine. 2026.
Some cognitive decline reversed after post-Omicron hospitalization
22.0% (460/2087)
By two years after discharge, 22.0% of hospitalized post-Omicron survivors had reversible cognitive decline, while 10.8% had irreversible decline and 67.1% maintained stable cognition.
This multicenter cohort included people hospitalized after Omicron infection, so its cognitive trajectories should not be generalized to everyone with Long COVID.
See the evidence
Hospitalized post-Omicron survivors with reversible cognitive decline by two years after discharge
22.0% (460/2087)
Qiu, Min et al.. Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.. Neuroprotection (Chichester, England). 2026.
Hospitalized post-Omicron survivors with irreversible cognitive decline two years after discharge
10.8% (226/2087)
Qiu, Min et al.. Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.. Neuroprotection (Chichester, England). 2026.
Hospitalized post-Omicron survivors who maintained stable cognitive function two years after discharge
67.1% (1401/2087)
Qiu, Min et al.. Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.. Neuroprotection (Chichester, England). 2026.
Fatigue, memory, and sleep problems remained prevalent after hospitalization
Across follow-up assessments, fatigue prevalence was 53-65%, memory/concentration difficulty 47-61%, and sleep disturbance 40-48% among adults previously hospitalized for COVID-19.
The longitudinal study followed previously hospitalized adults through 36 months. Its symptom burden may not represent people who were never hospitalized.
See the evidence
Fatigue prevalence across follow-up assessments through 36 months among adults previously hospitalized for COVID-19
53-65%
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
Memory/concentration difficulty prevalence across follow-up assessments through 36 months among adults previously hospitalized for COVID-19
47-61%
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
Sleep-disturbance prevalence across follow-up assessments through 36 months among adults previously hospitalized for COVID-19
40-48%
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
COVID-19 was associated with ischemic stroke and new Alzheimer's disease
One study associated COVID-19 with a higher ischemic stroke hazard. Another associated COVID-19 with a higher hazard of new-onset Alzheimer's disease among people aged 65+.
The stroke population beyond COVID-19 exposure is not specified, and neither study's reference group, absolute event rate, or design is available in this summary. These associations do not establish causation.
See the evidence
Ischemic Stroke Risk
+52% HR 1.52 (95% CI: 1.43-1.62)
Xie Y, et al. Long-term cardiovascular outcomes of COVID-19. Nature Medicine. 2022;28:583-590.
Vaccination dose count and age tracked progressive cognitive decline
Among hospitalized post-Omicron survivors, vaccination dose count was inversely associated with progressive cognitive decline, while age ≥60 years was associated with it.
These were associations from a Two-year cohort, not randomized comparisons. Dose and age reference categories and adjustment details are not available in this summary.
See the evidence
Number of vaccination doses was inversely associated with progressive cognitive decline after Omicron infection.
OR 0.69 95% CI: 0.55-0.87
Qiu, Min et al.. Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.. Neuroprotection (Chichester, England). 2026.
Age ≥60 years was associated with progressive cognitive decline after Omicron infection.
OR 4.31 95% CI: 1.47-12.65
Qiu, Min et al.. Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.. Neuroprotection (Chichester, England). 2026.
SARS-CoV-2 was associated with regional gray matter reduction
In UK Biobank, SARS-CoV-2 was associated with gray matter reduction in the orbitofrontal cortex and parahippocampal gyrus.
This is a structural brain outcome rather than a reported symptom or diagnosis. The comparison group and clinical significance are not available in this summary.
See the evidence
Brain Volume Loss
0.2-2.0% Gray matter reduction in orbitofrontal cortex and parahippocampal gyrus
Douaud G, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697-707.
Fatigue, memory difficulty, and sleep disturbance persisted
Across follow-up assessments, fatigue prevalence was 53-65%, memory/concentration difficulty 47-61%, and sleep disturbance 40-48%.
This longitudinal study followed adults previously hospitalized for COVID-19 through 36 months, so it does not represent all Long COVID populations.
Dizziness and coordination impairment worsened over follow-up
Dizziness prevalence increased over 36 months after COVID-19 hospitalization, while coordination impairment more than doubled.
These trajectories concern people previously hospitalized for COVID-19. The exact assessment points represented by the ranges are not detailed in this summary.
Study details & original results
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
Fatigue prevalence across follow-up assessments through 36 months among adults previously hospitalized for COVID-19
53-65%
Memory/concentration difficulty prevalence across follow-up assessments through 36 months among adults previously hospitalized for COVID-19
47-61%
Sleep-disturbance prevalence across follow-up assessments through 36 months among adults previously hospitalized for COVID-19
Cognitive decline sometimes reversed after post-Omicron hospitalization
22.0% (460/2087)
By two years after discharge, 22.0% had reversible cognitive decline, 10.8% had irreversible decline, and 67.1% maintained stable cognition.
This was a Two-year multicenter cohort of hospitalized survivors. Progressive cognitive decline was separately reported in 3.6%; its overlap with the irreversible category is not detailed in this summary.
Age and vaccination dose count tracked progressive decline
Age ≥60 years was associated with progressive cognitive decline, while vaccination dose count was inversely associated with it.
These were associations within a Two-year cohort of hospitalized post-Omicron survivors, not randomized comparisons. Reference categories and adjustment details are not available in this summary.
Study details & original results
Qiu, Min et al.. Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.. Neuroprotection (Chichester, England). 2026.
Hospitalized post-Omicron survivors with reversible cognitive decline by two years after discharge
22.0% (460/2087)
Hospitalized post-Omicron survivors with irreversible cognitive decline two years after discharge
10.8% (226/2087)
Hospitalized post-Omicron survivors who maintained stable cognitive function two years after discharge
67.1% (1401/2087)
Hospitalized post-Omicron survivors who showed progressive cognitive decline by two years
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 20 findingsOriginal results, comparisons and study details.
7 of 7 source groupsFindings stay together with their study.
SOURCE 356 findings
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
Qiu, Min et al.. Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.. Neuroprotection (Chichester, England). 2026.
Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection. Immunologic Research. 2021;69:205-211.
25-50%POTS-like syndrome in Long COVID patientsSource [21]
SOURCE 334 findings
Faseeh, Ahmar et al.. Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.. Medicine. 2026.
Ceban F, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain, Behavior, and Immunity. 2022;101:93-135.
Premraj L, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. Journal of the Neurological Sciences. 2022;434:120162.
Siow I, et al. Stroke as a Neurological Complication of COVID-19: A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases. 2021;30(3):105549.
Evans RA, et al. (PHOSP-COVID). Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation. Lancet Respiratory Medicine. 2021;9(11):1275-1287.
Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection. Immunologic Research. 2021;69:205-211.
Oaklander AL, et al. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. Neurology: Neuroimmunology & Neuroinflammation. 2022;9(3):e1146.
Varatharaj A, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875-882.
Wallukat G, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. Journal of Translational Medicine. 2021;19:28.
Faseeh, Ahmar et al.. Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.. Medicine. 2026.
Qiu, Min et al.. Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients.. Neuroprotection (Chichester, England). 2026.
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.